Differential Risk of Cancer Associated with Glucagon-like Peptide-1 Receptor Agonists: Analysis of Real-world Databases.

IF 1.5 4区医学 Q4 ENDOCRINOLOGY & METABOLISM

Endocrine Research Pub Date : 2022-02-01 Epub Date: 2021-08-30 DOI:10.1080/07435800.2021.1955255

Jiasheng Wang, Chang H Kim

{"title":"Differential Risk of Cancer Associated with Glucagon-like Peptide-1 Receptor Agonists: Analysis of Real-world Databases.","authors":"Jiasheng Wang, Chang H Kim","doi":"10.1080/07435800.2021.1955255","DOIUrl":null,"url":null,"abstract":"Background: Glucagon-like peptide 1 receptor agonists (GLP1Ra) are commonly used in type 2 diabetes mellitus (T2DM). However, differential risk of various cancers among GLP1Ra recipients is unknown.Methods: We inquired an aggregated electronic health record database, Explorys, and compared the adjusted odds ratio (aOR) of cancers between GLP1Ra and metformin users. Findings were validated in the FDA Adverse Event Reporting System (FDA FAERS).Results: From 1/2005 to 6/2019, we identified 619 340 and 64 230 patients in the metformin and GLP1Ra group, respectively. Within 5 years of starting antidiabetic medications, GLP1Ra was associated with significantly lower incident risk of prostate (aOR 0.81, p = .03), lung (aOR 0.81, p = .05), and colon cancer (aOR 0.85, p = .03), while the risk of thyroid cancer was significantly higher (aOR 1.65, p < .01). Similar findings were seen in the FDA FAERS database, where GLP1Ra was associated with lower risk of prostate (aOR 0.72, p = .08), lung (aOR 0.52, p < .01), colon cancer (aOR 0.82, p = .31), and higher risk of thyroid cancer (aOR 4.33, p < .01). In addition, with longer duration of GLP1Ra use, the risk of prostate, lung, and colon cancer further decreased, suggesting an exposure duration-response relationship.Conclusions: GLP1Ra is associated with lower risks of prostate, lung, and colon cancer, but higher risk of thyroid cancer.","PeriodicalId":11601,"journal":{"name":"Endocrine Research","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"15","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/07435800.2021.1955255","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/8/30 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 15

Abstract

Background: Glucagon-like peptide 1 receptor agonists (GLP1Ra) are commonly used in type 2 diabetes mellitus (T2DM). However, differential risk of various cancers among GLP1Ra recipients is unknown.

Methods: We inquired an aggregated electronic health record database, Explorys, and compared the adjusted odds ratio (aOR) of cancers between GLP1Ra and metformin users. Findings were validated in the FDA Adverse Event Reporting System (FDA FAERS).

Results: From 1/2005 to 6/2019, we identified 619 340 and 64 230 patients in the metformin and GLP1Ra group, respectively. Within 5 years of starting antidiabetic medications, GLP1Ra was associated with significantly lower incident risk of prostate (aOR 0.81, p = .03), lung (aOR 0.81, p = .05), and colon cancer (aOR 0.85, p = .03), while the risk of thyroid cancer was significantly higher (aOR 1.65, p < .01). Similar findings were seen in the FDA FAERS database, where GLP1Ra was associated with lower risk of prostate (aOR 0.72, p = .08), lung (aOR 0.52, p < .01), colon cancer (aOR 0.82, p = .31), and higher risk of thyroid cancer (aOR 4.33, p < .01). In addition, with longer duration of GLP1Ra use, the risk of prostate, lung, and colon cancer further decreased, suggesting an exposure duration-response relationship.

Conclusions: GLP1Ra is associated with lower risks of prostate, lung, and colon cancer, but higher risk of thyroid cancer.

查看原文本刊更多论文

与胰高血糖素样肽-1受体激动剂相关的不同癌症风险:真实世界数据库的分析。

背景:胰高血糖素样肽1受体激动剂(GLP1Ra)常用于2型糖尿病(T2DM)。然而，GLP1Ra受体中各种癌症的风险差异尚不清楚。方法:我们查询了一个汇总的电子健康记录数据库Explorys，并比较了GLP1Ra和二甲双胍使用者之间癌症的调整优势比(aOR)。研究结果在FDA不良事件报告系统(FDA FAERS)中得到验证。结果:从2005年1月至2019年6月，我们在二甲双胍和GLP1Ra组分别鉴定了619340例和64230例患者。5年内开始抗糖尿病的药物,GLP1Ra与前列腺癌的风险大大降低事件(优势比0.81,p = 03)、肺(优势比0.81,p = . 05)和结肠癌(优势比0.85,p = 03),而甲状腺癌的风险更高(优势比1.65,p p =。08)、肺(优势比0.52,p =。31页)和甲状腺癌的风险更高(优势比4.33,p结论:GLP1Ra与降低前列腺癌的风险,肺癌、结肠癌,但甲状腺癌的风险更高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Endocrine Research 医学-内分泌学与代谢

CiteScore

4.30

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： This journal publishes original articles relating to endocrinology in the broadest context. Subjects of interest include: receptors and mechanism of action of hormones, methodological advances in the detection and measurement of hormones; structure and chemical properties of hormones. Invitations to submit Brief Reviews are issued to specific authors by the Editors.